|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0024301,
umls-concept:C0032744,
umls-concept:C0033147,
umls-concept:C0040395,
umls-concept:C0205250,
umls-concept:C0233929,
umls-concept:C0600558,
umls-concept:C0679646,
umls-concept:C0681890,
umls-concept:C0936012,
umls-concept:C1425446,
umls-concept:C1515021,
umls-concept:C1547647
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2011-8-9
|
|
pubmed:abstractText |
The utility of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end of induction therapy is well documented in Hodgkin's and diffuse large B-cell lymphomas, but its role in follicular lymphoma (FL) remains undetermined. We investigated the prognostic significance of PET-CT performed after first-line therapy in patients with FL treated in the prospective Primary Rituximab and Maintenance (PRIMA) study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:CanioniDanielleD,
pubmed-author:DecaudinDidierD,
pubmed-author:EstellJaneJ,
pubmed-author:FabianiBettinaB,
pubmed-author:ForsythCecilyC,
pubmed-author:FournierMarionM,
pubmed-author:FulhamMichaelM,
pubmed-author:GabarreJeanJ,
pubmed-author:GarinEtienneE,
pubmed-author:GyanEmmanuelE,
pubmed-author:JanikovaAndreaA,
pubmed-author:LamyThierryT,
pubmed-author:SallesBrunoB,
pubmed-author:SallesGillesG,
pubmed-author:SeymourJohn FrancisJF,
pubmed-author:ShpilbergOferO,
pubmed-author:SonetAnneA,
pubmed-author:TillyHervéH,
pubmed-author:TrotmanJudithJ,
pubmed-author:Van Den NesteEricE,
pubmed-author:Vander BorghtThierryT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3194-200
|
|
pubmed:meshHeading |
pubmed-meshheading:21747087-Adult,
pubmed-meshheading:21747087-Aged,
pubmed-meshheading:21747087-Aged, 80 and over,
pubmed-meshheading:21747087-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:21747087-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21747087-Cyclophosphamide,
pubmed-meshheading:21747087-Disease-Free Survival,
pubmed-meshheading:21747087-Doxorubicin,
pubmed-meshheading:21747087-Female,
pubmed-meshheading:21747087-Humans,
pubmed-meshheading:21747087-Kaplan-Meier Estimate,
pubmed-meshheading:21747087-Lymphoma, Follicular,
pubmed-meshheading:21747087-Male,
pubmed-meshheading:21747087-Middle Aged,
pubmed-meshheading:21747087-Positron-Emission Tomography,
pubmed-meshheading:21747087-Prednisone,
pubmed-meshheading:21747087-Randomized Controlled Trials as Topic,
pubmed-meshheading:21747087-Tomography, X-Ray Computed,
pubmed-meshheading:21747087-Treatment Outcome,
pubmed-meshheading:21747087-Vincristine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
|
|
pubmed:affiliation |
Royal Prince Alfred Hospital and Sydney Medical School, University of Sydney, Sydney, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
